Volume 17

Issue 5

Article 3

2009

Simultaneous determination of plasma betamethasone disodium
phosphate and betamethasone in rabbit by high performance
liquid chromatography

Follow this and additional works at: https://www.jfda-online.com/journal

Recommended Citation
Cheng, W.-S.; Chen, J.-L.; and Chiang, C.-H. (2009) "Simultaneous determination of plasma
betamethasone disodium phosphate and betamethasone in rabbit by high performance liquid
chromatography," Journal of Food and Drug Analysis: Vol. 17 : Iss. 5 , Article 3.
Available at: https://doi.org/10.38212/2224-6614.2588

This Original Article is brought to you for free and open access by Journal of Food and Drug Analysis. It has been
accepted for inclusion in Journal of Food and Drug Analysis by an authorized editor of Journal of Food and Drug
Analysis.

348
Journal of Food and Drug Analysis, Vol. 17, No. 5, 2009, Pages 348-356

藥物食品分析

第十七卷

第五期

Simultaneous Determination of Plasma Betamethasone
Disodium Phosphate and Betamethasone in Rabbit by
High Performance Liquid Chromatography
WEN-SHENG CHENG1, JIIN-LONG CHEN2 AND CHIAO-HSI CHIANG2*
1.

Department of Clinical Pharmacy, National Army Beitou Hospital, 60 Sinmin Road, Beitou District, Taipei, Taiwan, R.O.C.
2.
School of Pharmacy, National Defense Medical Center, 161 Minchuan East Road, Sec. 6, Taipei, Taiwan, R.O.C.
(Received: April 3, 2008 ; Accepted: August 10, 2009)

ABSTRACT
Betamethasone disodium phosphate (BDP), a hydrophilic prodrug of betamethasone (BTM), was rapidly converted into betamethasone in blood following intravenous administration. In this study, we established an analytical method of high performance
liquid chromatography (HPLC) to simultaneously determine BDP and its free base BTM in plasma samples. The calibration curves
demonstrate good linearity (BDP, R 2 = 0.99999; BTM, R 2 = 0.99997) and reproducibility within a range from 50 ng/mL to 6000 ng/
mL. The analytical method was applied to determine the pharmacokinetics of BTM and BDP following intravenous bolus injection
of BDP in New Zealand white rabbits (0.4 mg/kg). The determined pharmacokinetic parameters were listed as follows: for BDP,
half-life: 13.69 ± 2.70 min (Mean ± SEM, n = 6), clearance: 3.96 ± 0.45 mL/min/kg and distribution volume: 72.9 ± 9.67 mL/kg; for
BTM, half-life: 228.58 ± 72.9 min, clearance: 3.50 ± 1.18 mL/min/kg, and distribution volume: 327.57 ± 69.9 mL/kg. The established
HPLC analytical method and related pharmacokinetic parameters of BDP and BTM might be potentially applied to use these drug
administration in the treatment of respiratory relevant diseases.
Key words: betamethasone disodium phosphate (BDP), betamethasone (BTM), high performance liquid chromatography (HPLC)

INTRODUCTION
Corticosteroids are the first-line drugs in the treatment of chronic obstruction pulmonary diseases (1).
Recently, these drugs also play important roles in the
treatment of severe acute respiratory syndrome (SARS)
(2-4)
. Three dosage forms of corticosteroids, including
oral, parenteral and inhalation preparations, are widely
used in clinical therapy. Respiratory distress syndrome
(RDS) is one of the most common causes of morbidity
and mortality in premature newborns especially in twins.
In the last stages of pregnancy, 34 to 37 gestational
weeks, type II alveolar cells of fetus normally produce
surfactant for reducing the surface tension of alveolar
lining fluid, and the surfactant is important for neonate
at birth to expand air sacs and breathe normally. In the
past, betamethasone (BTM), a highly potent anti-inflammatory corticosteroid, has been shown to reduce the
incidents and severity of RDS in premature neonates
when it is administrated antenatally to women who are
* Author for correspondence. Tel: +886-2-87923100 ext. 18894;
Fax: +886-2-87924838; E-mail: cch@mail.ndmctsgh.edu.tw

at risk of delivering prematurely(5). Consequently, BTM
is further applied to prevent neonatal RDS(6). In addition,
postnatal corticosteroid therapy significantly facilitates
extubation and shortens the duration of intubation in
preterm/extremely low birth weight infants (7). The ester
derivatives of BTM, including benzoate, dipropionate
and valerate, are poorly water-soluble agents, and
commonly used in powder and suspension dosage forms.
Betamethasone disodium phosphate (BDP) is a hydrophilic prodrug of BTM and is rapidly hydrolyzed to
BTM in blood for further distributing into target tissues
to achieve therapeutic effects. BDP is a water soluble
agent which had been investigated and prepared as
BDP-loaded microparticles for pulmonary delivery to
extend the resident time of BDP in lung(8,9). However,
BTM also causes severe adverse effects in human infant
such as impairing growth and increasing incidence of
central nervous system abnormalities. Thus, a rapid and
convenient analytical method for measuring BDP and
BTM concentrations in plasma would provide important
information to the drug regimen of BDP for adjusting
dose and minimizing side effects.
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Recently, high performance liquid chromatography
(HPLC) has been employed to measure BTM level in
biological fluids(10,11). In these methods, authors assumed
that BDP is rapidly hydrolyzed to BTM in plasma so
that BDP and BTM are not separated during sample
preparation in their HPLC analysis. The approach often
overestimates the blood levels of BTM, especially in
initial time points. Although BDP can also be analyzed
by HPLC methods (12,13), BDP and BTM analyses usually
involve two separate sample preparations associated with
individual HPLC determinations. Thus, the analytical
method for BDP and BTM in plasma sample need to be
improved for rapid and efficient measurement of their
concentrations.
Rabbit has body weight and size similar to human
newborn. Rabbit model has been frequently used for
investigating neonatal pulmonary function(14-16). Thus,
rabbit could be a suitable animal model for investigating
BDP and BTM pharmacokinetics, which in turns can
be applied in the prevention or treatment of neonate
RDS. In this study, we intended to establish an HPLC
analytical method for simultaneously determining
plasma BDP and BTM concentrations. In addition,
the established analytical method was applied to
investigate the pharmacokinetics of BDP and BTM
following intravenous (IV) administration of BDP in
rabbits. The specific aims of this study were to evaluate
the established HPLC method including precision and
reproducibility. In addition, the pharmacokinetic model
of BDP and BTM was further proposed to measure their
pharmacokinetic parameters.

MATERIALS AND METHODS
I. Chemicals
Betamethasone disodium phosphate (BDP) was
purchased from Sicor (Milan, Italy). Betamethasone
(BTM), hydrocortisone (HC) and xylazine HCl were
from Sigma (St. Louis, MO, USA). Prednisolone sodium
phosphate (PSP) was gifted from China Chemical Pharmaceutical Incorporation (Taipei, Taiwan). Ketamine
HCl was from Nang Kuang Pharmaceutical Co. (Tainan,
Taiwan). Heparin sodium injection was from Novo
Nordisk (Bagsvaerd, Denmark). Other chemicals were of
either analytical or reagent grade.
II. Liquid Chromatography
BDP and BTM were determined by an HPLC system
(Jasco Inc., Tokyo, Japan), including a pump (PU-980),
an autosampler (851-AS) associated with a sample loop
(50 μL), and a UV detector (UV-975). Analyte peaks
were determined using an integration software (SISC
32, Scientific Information Service Corporation, Taipei,
Taiwan). Separations were achieved using an Intersil C18

column (ODS-80Å 5 μm, 250 × 4.6 mm, GL Science,
Tokyo, Japan). The mobile phase consisted of 0.07 M
KH 2PO 4 and CH 3OH with a ratio of 60/40 (v/v) which
was filtered through a 0.45 μm membrane filter (HA,
Millipore Corporation, Bedford, MA, USA) and degassed
by sonication. The flow rate of the mobile phase was set
at 1 mL/min and run at ambient temperature. The HPLC
elute was monitored by absorbance at 245 nm.
III. Plasma Obtainment
New Zealand white rabbits, weighing 2 - 2.5 kg,
either sex, were used in the study. Animals were handled
according to a protocol approved by the Animal Care
and Use Committee, National Defense Medical Center
(Taipei, Taiwan). Rabbits were anesthetized using
ketamine HCl (70 mg/kg) and xylazine HCl (10 mg/kg)
via intramuscular injection. Blood sample was withdrawn from the ear central vein of rabbit via a cannula
and collected into a test tube (rinsing with 10 μL of 100
IU/mL heparin sodium) with Teflon-lined screw cap. The
blood sample was immediately mixed with 1 M sodium
arsenate (20 μL for 1 mL blood sample) and centrifuged
at 2800 rpm for 20 min at 4°C (Sorvall RT7, Newton, CT,
USA). The plasma supernatant was then collected and
frozen at -20°C. Samples were analyzed within one week
in the same day.
IV. Sample Preparation
Plasma concentrations of BDP and BTM were
measured by HPLC using PSP and HC as internal standards. The procedure of sample preparation is briefly
described in Scheme 1. PSP and HC solutions, each
30 μL (concentration: 50 μg/mL), were added to 1 mL
plasma in a glass tube and mixed with 2 mL of acetonitrile for deproteinization by vortex 10 s. After mixing,
the mixture was centrifuged at 2800 rpm for 2 min in
a centrifuge (Sorvall RT7, Newton, CT, USA) at 4°C.
The supernatant was transferred into another glass tube
containing 2 mL of ethyl acetate. This tube was capped
with a Teflon-lined screw cap and mixed for 1 min. After
centrifuging at 2800 rpm for 2 min at 4°C, the mixture
was separated into two portions, organic layer (S1) on
top and aqueous layer (S2) at the bottom. S1 was transferred into another tube. Then, 0.1 N NaOH (250 μL)
was added into the tube and mixed for 10 s, the supernatant was immediately transferred into a new tube after
standing 5 s. Following, 500 μL of water was added to
wash the alkalized liquid by vortex 10 s and standing
5 s. The upper layer was withdrawn and evaporated
to obtain dried residue by using a centrifuging vapor
condenser (Eyela, Tokyo, Japan). For S2, 5 N hydrochloric acid solution (40 μL), sodium chloride (300 mg)
and ethyl acetate (5 mL) were added into the tube and
completely mixed by vortex 10 s. After centrifuging for
3 min, the upper layer was withdrawn and evaporated

350
Journal of Food and Drug Analysis, Vol. 17, No. 5, 2009

1 mL plasma
50 µL BDP
50 µL BTM
30 µL PSP (internal standard)
30 µL HC (internal standard)

1. ACN 2 mL, mixing
2. Centrifuging

the upper layer (S1)
Washed by : 1. 0.1 N NaOH
2. H2 O

Transfer supernatant
into another tube

1. Evaporation
2. Reconstituted by
mobile phase
HPLC

upper

combining

the lower layer(S2)
1. Ethyl acetate 2 mL,
mixing
lower
2. Centrifuging

HPLC
HPLC

1. After 5 N HCl acidified, then ethyl acetate
2. Centrifuging
3. Withdraw the upper layer

1. Evaporation
2. Reconstituted by
mobile phase

Scheme 1. The procedure for the treatment of plasma sample
PSP: Prednisolone sodium phosphate
BDP: Betamethasone disodium phosphate
HC: Hydrocortisone
BTM: Betamethasone
S1: For determining BTM.
S2: For determining BDP.

to obtain dried residue. The dried residues of S1 and S2
were separately reconstituted in 200 μL of mobile phase
which were analyzed either alone or combined together
in HPLC analyses.
V. Calibration Curve and QC Preparation
A calibration curve was established from analyzing
spiked samples, which are obtained by the addition of
known quantities of BDP, BTM, HC and PSP mixture
to aliquots of plasma and prepared as described above
for sample preparation. The concentrations for BDP
and BTM were 50, 100, 200, 500, 1000, 3000 and
6000 ng/mL. The peak-height ratios of BDP or BTM
to internal standard were plotted against the prepared
concentrations. Linearity was determined from all
concentrations (50-6000 ng/mL). The calibration curve
of each compound was determined by weighted leastsquare linear regression analysis using the weight of 1/
concentration 2.

Quality control (QC) samples at 4 levels, 50, 100,
1000, and 5000 ng/mL were prepared and analyzed
to monitor the calibration curves. Sample extraction
and HPLC analysis for QC samples were carried out as
described above.
VI. Stability Studies
Two spiked plasma samples with concentrations of
BDP, 100 and 1000 ng/mL, were used as low and high
levels for stability studies. The spiked samples including
high and low levels were divided into four groups as
A, B, C, and D, each group was run triplicate. Group A
samples were analyzed immediately to determine the
initial drug concentration of spiked samples. Group B
samples were analyzed after standing at room temperature for 4 hrs. These samples were used to mimic the
required time in the preparation of the HPLC sample
during analytical process. Group C samples were stored
at -20°C for 6 days and thawed at room temperature
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before analysis. Group D samples were stored at -20°C
for 24 h and thawed at room temperature, this freezethaw cycle (FTC) was repeated another twice before
analysis. The stability studies of BTM in plasma were
conducted as the similar process of BDP.

(a)
kh

BDP
X’
(b)

Central compartment

Peripheral compartment

VII. Pharmacokinetic Study

k12

New Zealand white rabbits, 2-2.5 kg either sex,
were used in the study of pharmacokinetics. Rabbits
were anesthetized using ketamine HCl (70 mg/kg) and
xylazine HCl (10 mg/kg). BDP with a dose of 0.4 mg/kg
was intravenously injected through the ear margin vein
of rabbit. Blood samples were collected via a cannula
in the femoral artery of rabbits, at predose, 5, 10, 15,
30, 60, 90, 120, 180 and 240 min. Blood samples were
treated as the same procedure described in sections of
Plasma obtainment and Sample preparation. Plasma
concentrations of BDP and BTM were determined
by the established HPLC method. The time courses
of BDP and BTM plasma levels were fit by a proposed
pharmacokinetic model as Scheme 2. In this model, BDP
was considered to be rapidly and completely converted
into BTM in blood, two compartment open model was
proposed for the disposition of BTM. Then, the time
course of BDP concentration (CBDP) in plasma could be
described as follows:
CBDP = CBDP0 e

k10 =

–kht
αβ ( A+ B )
Aβ +initial
Bα
the

αβ ( A+ B )
Aβ(1)
+ Bα

AB ( β −α ) 2

BDP
X’

k'h

X2

BTM
X1
k21
k10

dX '
= −kh X '
dt

(1)

dX '
= k h' X '+ k 21 X 2 − (k12 X 1 + k10 X 1)
dt

(2)

Scheme 2. Pharmacokinetic models of betamethasone sodium
phosphate (BDP) and betamethasone (BTM) following intravenous
administration of BDP in rabbits.
(a) BDP and (b) BTM.
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Eq. 1 and Eq. 2 were fit by using WinNonlin
computer program (V3.0, SCI software, Mountain
View, CA, USA) in order to obtain the pharmacokinetic
parameters of BDP and BTM in rabbit.
The pharmacokinetic parameters of BDP were
obtained as follows:
k h = hydrolysis rate constant (or elimination rate
constant)
half-life = 0.693/k h

AUC0~∞ =

α

CCBDP
BDP00
kkhh

Clearance = Dose/AUC0~∞
In addition, the pharmacokinetic parameters of
BTM were also obtained as follows:
k’h = input rate constant
α = distribution rate constant
β = elimination rate constant

RESULTS
I. Chromatograms
The chromatograms of BDP and BTM associated
with their two internal standards, PSP (for BDP) and
HC (for BTM) are illustrated in Figure 1. The HPLC
retention times of PSP, BDP, HC and BTM were 5.3, 6.5,
8.3 and 11.8 min, respectively. Four compounds were
completely separated in the established HPLC method.
The endogenous components of plasma did not interfere
with the analyses of BDP and BTM. (Figure 1C)
II. Calibration Curves of BDP and BTM
The regression lines had good linearity ranging
from 50 to 6000 ng/mL for BDP and BTM. The linear
regression equations of BDP and BTM calibration curves
were constructed in triplicate determinations and listed
as follows:

h
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(a)

(b)

25

(c)
25

25
HC (8.3)

20

HC

PSP (5.3)

20

20

15

15

15

mV

mV
10

mV

BDP (6.5)

BTM (11.8)

0

5

5

5

0

0

10

PSP

10

PSP

10

5

HC

BTM

BDP

0
0

5

Time (min)

10

0

Time (min)

5

10

Time (min)

Figure 1. Chromatograms of betamethasone disodium phosphate (BDP), betamethasone base (BTM) and two internal standards: prednisolone
sodium phosphate (PSP) and hydrocortisone (HC). (a). Drugs in mobile phase (BDP: 500 ng/mL, BTM: 500 ng/mL, PSP: 50 μg/mL, HC: 50 μg/
mL); (b). pre-dosing; and (c). 1 hr post-dosing (BDP: 540 ng/mL; BTM: 1090 ng/mL).

Table 1. Reproducibility of inter-day and intra-day analyses for BTM and BDP
BTM
Nominal concentration (ng/mL)

BDP
Error (%)

CV (%)

50

2.11

17.97

100

-6.58

1000
5000

Nominal concentration (ng/mL)

Error (%)

CV (%)

200

-5.18

12.21

13.18

500

-3.94

13.16

6.78

3.85

1000

-0.64

7.32

3.52

8.91

5000

-2.18

10.35

50

0.23

8.21

200

-12.12

14.57

100

13.38

11.46

500

-8.12

11.90

1000

14.35

9.39

1000

-8.89

13.65

5000

8.42

6.38

5000

-9.72

12.28

Intra-day*

Inter-day*

*n = 5

BDP: y = 0.000393 x + 0.001055 (R 2 = 0.99999)
BTM: y = 0.000308 x + 0.00294 (R 2 = 0.99997)
III. Reproducibility
Reproducibility of the measurement was evaluated
by within-day and between-day analyses and illustrated
by the accuracy (error) and the precision (coefficient of
variation, CV), as shown in Table 1. The determined
concentrations had variations within ± 15%, except 50

ng/mL of BTM in within-day associated with a higher
CV (17.97%), but the value is less than 20%(17). The
results of the reproducibility were within an acceptable
range.
IV. Stability
Two levels (100 and 1000 ng/mL) of BDP and BTM
were investigated for drug stabilities during sample
storage or sample preparation. For FTC experiments, we
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observed a significant reduction of HPLC peak areas for
BDP, about 30% in 100 ng/mL and 10% in 1000 ng/mL
by comparing the initial peak area of BDP (Group A).
During the storages of 4 h at room temperature and 6 days
at -20°C, BDP peak areas of two levels did not show any
significant reduction. Nearly 5% reduction was observed
for 100 ng/mL of BTM in the FTC experiment. There
were no any significant reductions of BTM concentrations
in other stability studies (data not shown).

Concentration (ng/mL)
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10000

(a)

1000

100

0

mean

SEM

Vb

mL/kg

72.92

9.67

29.66

kh

min-1

0.0597

0.0114

42.68

min

13.69

2.70

44.05

mL/min/kg

3.96

0.45

25.61

min ng/mL

0.107 x 106

11952

25.06

Parameter

half-life
Clearancec
AUC0~∞d
a

b

a

CV (%)

∞
..∞

CBDP
dt ==
AUC0~∞= ∫ C
BDPdt
..00

150

200

250

300

(b)

1000

100

0

50

100

150

200

250

300

Time (min)

c

sample size = 6; V = Dose/k h AUC0~∞; Clearance = Dose/AUC0~∞;

d

Concentration (ng/mL)

unit

a

100

Time (min)
10000

Table 2. Pharmacokinetic parameters of BDP in New Zealand white
rabbits following the intravenous administration of BDP with a dose
of 0.4 mg/kg.

50

CBDP
C
BDP00
kkhh

Figure 3. Time course of betamethasone plasma level following the
intravenous administration of betamethasone disodium phosphate
with a dose of 0.4 mg/kg. (a) Individual data and (b) fit curve and
mean data (Mean ± SEM, n = 6)
, , , , × and * represented different rabbits.

V. Pharmacokinetics
(a)

Concentration (ng/mL)

10000

1000

100

0

10

20

30

40

50

60

70

50

60

70

Time (min)
(b)

Concentration (ng/mL)

10000

1000

100
0

10

20

30

40

Time (min)

Figure 2. Time course of betamethasone disodium phosphate (BDP)
plasma level in New Zealand white rabbits following the intravenous
administration of BDP with a dose of 0.4 mg/kg. (a) Individual data
and (b) fit curve and mean data (Mean ± SEM, n = 6).
, , , , × and * represented different rabbits.

Following the intravenous administration of BDP
in rabbits, the plasma profiles and pharmacokinetic
parameters of BDP are illustrated in Figure 2 and listed
in Table 2, respectively. After 60 min, BDP plasma levels
could not be determined due to below the quantitative
limit. In addition, BDP levels rapidly declined following
first-order kinetics with a mean rate constant of
0.0597 ± 0.0114 min-1 (Mean ± SEM, n= 6) and a mean
elimination half-life of 13.69 ± 2.70 min. In vivo study,
BDP has been reported to be quickly hydrolyzed by
phosphatase associated with a half-life about 10 min
which is consistent with our study results (18). The volume
distribution of BDP was 72.9 ± 9.67 mL/kg which was
close to the volume of blood.
Following the intravenous administration of BDP,
the plasma profile and pharmacokinetic parameters
of BTM are illustrated in Figure 3 and listed in Table
3, respectively. The proposed three exponential-term
equation [C=A exp(-αt) + B exp(-βt)+N exp(-k’ht)] was
fitted with BTM experimental points very well. The BTM
plasma profile was noticed with a peak concentration
and time as 816 ± 162 ng/mL (Mean ± SEM, n = 6) and
19.17 ± 2.62 min, respectively. The fit rate constant
for hydrolyzing BDP to BTM (0.0474 ± 0.022 min -1)
was slightly less than the elimination rate constant of
BDP. The distribution and elimination rate constants of
BTM were 0.1558 ± 0.023 and 0.0040 ± 0.00094 min-1,
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Table 3. Pharmacokinetic parameters of BTM following intravenous
administration of BDP with a dose of 0.4 mg/kg in New Zealand
white rabbits.
Parameter*

mean

SEM

-1

0.0474

0.022

α

min

-1

0.1558

0.023

β

min-1

0.0040

0.00094

-1

0.0124

0.0051

-1

0.0593

0.016

-1

0.0882

0.038

k’h

k10
k12
k21

unit
min

min
min
min

α-t1/2

min

5.01

0.957

β-t1/2

min

228.58

72.9

mL/kg

327.57

69.9

mL/min/kg

3.50

1.18

min nmol/mL

479.58

121.99

Vd
Clearance
AUC

*pharmacokinetic parameters were determined by the proposed
model in Scheme 2.

respectively. Due to its short half-life, the distribution
phase was almost finished as the peak time of BTM.
Thus, a linear line was obtained in semi-log scale after
50 min. Furthermore, the terminal elimination halflife and total body clearance of BTM were obtained
to be 228.58 ± 72.9 min and 3.50 ± 1.18 mL/min/kg,
respectively.

DISCUSSION
In this study, we established an HPLC method for
simultaneously determine BDP and BTM concentrations
in plasma using two internal standards. This method
demonstrated good sensitivity and specificity for BDP and
BTM measurements. The lower limit of quantitation for
both analytes was 50 ng/mL. Petersen et al. previously
reported HPLC methods for determining dispositions
of betamethasone and its phosphate ester by analyzing
plasma levels of BTM and BDP separately, and using
different sample preparation methods associated with two
different HPLC analyses(6,12). In this study, we modified
their methods by applying dual internal standards, PSP
for BDP and HC for BTM, to achieve a simple and more
convenient HPLC determination. In sample preparation,
two treated samples either from organic (containing
BTM) or aqueous (containing BDP) layer extractions of
plasma sample were combined together for single injection to simultaneously determine both BDP and BTM
levels in once. Although the established HPLC analytical
method involved several steps in sample preparation,
the yields of BDP and BTM were good (BDP: 79.68%

± 1.98% and BTM: 78.37% ± 1.47%, for 100 ng/mL
concentration, n = 6) with acceptable precision and accuracy. Furthermore, the HPLC method was further applied
in pharmacokinetic study of BTM and BDP.
Recently, analytical methods of liquid chromatography/tandem mass spectrometry (LC/MS/MS) are also
established for measuring BTM concentration in plasma
sample. The analytical methods demonstrate excellent
sensitivity (0.1~2 ng/mL) for BTM(11,19). However, LC/
MS/MS methods usually involve complicate solid-phase
extraction for sample preparation and can only determine BTM concentration in plasma. In addition, the
approach of LC/MS/MS demands higher expense for
instrument maintenance. Thus, our established analytical method with UV detection might be more suitable
for routine measurement of BTM and BDP in plasma
samples. Furthermore, our analytical method also
demonstrated good sensitivity to enable measuring BTM
levels at initial time points for characterizing the absorption peak of BTM following intravenous administration
of BDP. Samtani et al., also reported an HPLC method
for measuring BDP and BTM plasma concentrations(13).
Although this method has an advantage for using small
sample volumes (50 μL of sample) in analysis, the analytical method is less sensitive with quantitative limits of
300 ng/mL for BTM and 500 ng/mL for BDP. Consequently, the HPLC method could not be applied for determining the complete pharmacokinetic parameter easily
due to some important data points below detection limits.
According to the studies of Tamvakopoulos et al.(11)
and Samtani et al.(19), the terminal half-lives of BTM
in rat and ewe (body weight about 70 kg) were 2.02 and
3.95 hr, respectively. In comparison to our HPLC study
results, the terminal half-life of BTM in rabbit was 3.8
hr (228 min) similar to that in ewe but different from
rat. The difference might be due to different species of
animals or other factors. The body weight of ewe is
similar to a pregnant woman so that it is frequently used
as a suitable animal for research related to pregnant
woman. It is interesting to obtain about equal half-lives
for BTM in ewe and rabbit.
Pharmacokinetics of BTM have been studied in
healthy adults and pregnant women(6,12), BTM with a
mean terminal half-life and clearance as follows: 6 h and
178 mL/min for healthy adults; 4 h and 287 mL/min for
pregnant women. In our study, we determined the terminal
elimination half-life and clearance of BTM in rabbits
to be 3.8 hr and 3.5 mL/min/kg, respectively. The results
were close to the reported pharmacokinetic parameters of
pregnant women(12). In pregnant woman study, the average
body weight of 13 subjects at 76 kg obtained the clearance
of BTM as 3.8 mL/min/kg (287 mL/min divided 76 kg). In
addition, Trenque et al. also investigated BTM disposition
in rabbits and obtained the elimination half-life and clearance of BTM to be 2 hr and 2.1 mL/min(10), respectively,
which are significantly lower than those of our study
results. It was possible that BTM concentrations in plasma

355
Journal of Food and Drug Analysis, Vol. 17, No. 5, 2009

included a significant portion of BDP in Trenque et al.
study, which led to overestimate the BTM plasma levels
at early time points due to no further separating BDP and
BTM in HPLC analysis(10).
According to our proposed pharmacokinetic model,
in vivo hydrolysis rate constant for converting BDP to
BTM was calculated from the slope by plotting logarithm
BDP concentration versus time to be 0.0579 min-1. The
value was slightly higher than the input rate constant of
BTM (0.0474 min-1). The decline of BDP level in plasma
was not only via the hydrolysis pathway, but a small
portion of BDP (about 18%) might also be eliminated by
renal excretion due to the hydrophilicity of BDP. Both
BTM and BDP formulations have been used in clinical
trials to improve precocious fetal lung maturation(19).
The severity of fetal growth restriction increases as the
number of maternal BTM injections increases. Therefore,
the pharmacokinetics of BTM in the fetal circulation is
important for reducing the side effects of fetal growth
restriction. Because the body weight and size of rabbit
are similar to human fetal, the BDP and BTM pharmacokinetics of rabbits might be further investigated to apply
in human fetal for optimizing antenatal glucocorticoid
treatment.
In conclusion, we established an HPLC analytical
method for simultaneously determining BDP and BTM in
plasma samples. The method was capable of measuring
BDP and BTM at early time points to characterize the
pharamacokinetics of BDP and BTM following intravenous injection. The analytical method was simple and
more convenient for routine measurement of BDP and
BTM in plasma which might be applied to optimize the
glucocorticoid treatment in respiratory relevant diseases.
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